Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response

Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response

ObjectiveCurrent knowledge on the actions of tofacitinib on cytokine signaling pathways in rheumatoid arthritis (RA) is based on in vitro studies. Our study is the first to examine the effects of tofacitinib treatment on Janus kinase (JAK) - signal transducer and activator of transcription (STAT) pa...

Description complète

Détails bibliographiques
Auteurs principaux: Maaria Palmroth, Krista Kuuliala, Ritva Peltomaa, Anniina Virtanen, Antti Kuuliala, Antti Kurttila, Anna Kinnunen, Marjatta Leirisalo-Repo, Olli Silvennoinen, Pia Isomäki
Format: Article
Langue:English
Publié: Frontiers Media S.A. 2021-09-01
Collection:Frontiers in Immunology
Sujets:
rheumatoid arthritis
cytokines
JAK inhibitor
monocytes
T cells
B cells
Accès en ligne:https://www.frontiersin.org/articles/10.3389/fimmu.2021.738481/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.738481/full

Documents similaires